248 related articles for article (PubMed ID: 8768861)
1. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease.
Salvi M; Girasole G; Pedrazzoni M; Passeri M; Giuliani N; Minelli R; Braverman LE; Roti E
J Clin Endocrinol Metab; 1996 Aug; 81(8):2976-9. PubMed ID: 8768861
[TBL] [Abstract][Full Text] [Related]
2. Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking.
Salvi M; Pedrazzoni M; Girasole G; Giuliani N; Minelli R; Wall JR; Roti E
Eur J Endocrinol; 2000 Aug; 143(2):197-202. PubMed ID: 10913938
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of cytokines in children and adolescents with Graves' disease and non-toxic nodular goiter.
Bossowski A; Urban M
J Pediatr Endocrinol Metab; 2001 Jun; 14(6):741-7. PubMed ID: 11453524
[TBL] [Abstract][Full Text] [Related]
4. Influence of thyroxine on serum soluble interleukin-2 receptor alpha levels in thyroid disorders.
Zwirska-Korczala K; Berdowska A; Jochem J; Sitkiewicz A; Birkner E; Polaniak R; Jedrzejowska-Szypułka H; Korzonek-Szlacheta I
J Clin Pharm Ther; 2004 Apr; 29(2):151-6. PubMed ID: 15068404
[TBL] [Abstract][Full Text] [Related]
5. CD8+CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves' orbitopathy and correlate with disease activity.
Slowik M; Urbaniak-Kujda D; Bohdanowicz-Pawlak A; Kapelko-Slowik K; Dybko J; Wolowiec D; Jazwiec B; Daroszewski J
Endocr Res; 2012; 37(2):89-95. PubMed ID: 22489922
[TBL] [Abstract][Full Text] [Related]
6. Soluble intercellular adhesion molecule-1 (sICAM-1) concentrations in Graves' disease patients followed up for development of ophthalmopathy.
De Bellis A; Di Martino S; Fiordelisi F; Muccitelli VI; Sinisi AA; Abbate GF; Gargano D; Bellastella A; Bizzarro A
J Clin Endocrinol Metab; 1998 Apr; 83(4):1222-5. PubMed ID: 9543145
[TBL] [Abstract][Full Text] [Related]
7. Increased levels of serum interleukin-18 in Graves' disease.
Miyauchi S; Matsuura B; Onji M
Thyroid; 2000 Sep; 10(9):815-9. PubMed ID: 11041460
[TBL] [Abstract][Full Text] [Related]
8. [The influence of corticosteroids on IL-6/IL-6R system in patients with Graves' ophthalmopathy].
Myśliwiec J; Kretowski A; Topolska J; Stepień A; Kinalska I
Pol Arch Med Wewn; 2002 Aug; 108(2):739-44. PubMed ID: 12476893
[TBL] [Abstract][Full Text] [Related]
9. [A study of cytokine expression in peripheral blood of patients with Graves' ophthalmopathy].
Tang L; Luo Q; Zhou X; Xia R
Zhonghua Yan Ke Za Zhi; 2002 Mar; 38(3):165-7. PubMed ID: 11955323
[TBL] [Abstract][Full Text] [Related]
10. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE
J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
[TBL] [Abstract][Full Text] [Related]
11. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y
J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
[TBL] [Abstract][Full Text] [Related]
12. The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy.
Molnár I
Autoimmunity; 2007 Feb; 40(1):31-7. PubMed ID: 17364495
[TBL] [Abstract][Full Text] [Related]
13. Remission and recurrence of hyperthyroid Graves' disease during and after methimazole treatment when assessed by IgE and interleukin 13.
Komiya I; Yamada T; Sato A; Kouki T; Nishimori T; Takasu N
J Clin Endocrinol Metab; 2001 Aug; 86(8):3540-4. PubMed ID: 11502776
[TBL] [Abstract][Full Text] [Related]
14. IL-6 and soluble IL-6 receptor levels change differently after surgery both in the blood and in the operative field.
Hisano S; Sakamoto K; Ishiko T; Kamohara H; Ogawa M
Cytokine; 1997 Jun; 9(6):447-52. PubMed ID: 9199879
[TBL] [Abstract][Full Text] [Related]
15. Decreased serum level of IL-7 in patients with active Graves' disease.
Motylewska E; Nieć M; Siejka A; Komorowski J; Ławnicka H; Świętosławski J; Stępień H
Cytokine; 2015 Oct; 75(2):373-9. PubMed ID: 26113403
[TBL] [Abstract][Full Text] [Related]
16. Cytokines serum levels as the markers of thyroid activation in Graves' disease.
Komorowski J; Jankiewicz J; Robak T; Błasińska-Morawiec M; Stepień H
Immunol Lett; 1998 Feb; 60(2-3):143-8. PubMed ID: 9557956
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.
Robak T; Wierzbowska A; Błasińska-Morawiec M; Korycka A; Błoński JZ
Mediators Inflamm; 1999; 8(6):277-86. PubMed ID: 10815616
[TBL] [Abstract][Full Text] [Related]
18. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
[TBL] [Abstract][Full Text] [Related]
19. Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid.
Desgeorges A; Gabay C; Silacci P; Novick D; Roux-Lombard P; Grau G; Dayer JM; Vischer T; Guerne PA
J Rheumatol; 1997 Aug; 24(8):1510-6. PubMed ID: 9263143
[TBL] [Abstract][Full Text] [Related]
20. Intercellular adhesion molecule-1 (ICAM-1) in the sera of patients with Graves' disease: correlation with disease activity and treatment status.
Fukazawa H; Yoshida K; Kaise N; Kiso Y; Sayama N; Mori K; Kikuchi K; Aizawa Y; Rikimaru A; Abe K
Thyroid; 1995 Oct; 5(5):373-7. PubMed ID: 8563475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
